IONS · Ionis Pharmaceuticals Inc · Webcasts, Transcripts & Audio
$29.06
+1.75 (+6.41%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$4.84B
Shares
166.55M
Volume · Nov 13
5.95M
Avg daily vol (3M)
3.8M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Ionis Pharmaceuticals Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Ionis Pharmaceuticals Inc (IONS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-09
Ionis Pharmaceuticals Inc (IONS) Q3 2026 Earnings Call
Revenue
$242.72M
▲ 54.9% YoY Diluted EPS
$-0.66
Gross margin
98.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-16
Ionis Pharmaceuticals Inc (IONS) September 16, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-10
Ionis Pharmaceuticals Inc (IONS) September 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-29
Ionis Pharmaceuticals Inc (IONS) Q2 2026 Earnings Call Transcript
Positive tone
Tringolza (Tryngolza) SHTG launch
Tringolza FCS commercial execution
Eplontersin ATTR cardiomyopathy Phase 3 disappointment
Revenue
$267.95M
▼ 40.7% YoY Diluted EPS
$-0.69
▼ 198.6% YoY Gross margin
99.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-10
Ionis Pharmaceuticals Inc (IONS) June 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-19
Ionis Pharmaceuticals Inc (IONS) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
Ionis Pharmaceuticals Inc (IONS) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-29
Ionis Pharmaceuticals Inc (IONS) Q1 2026 Earnings Call Transcript
Confident tone
Tryngolza (olezarsen FCS) launch momentum
DAWNZERA (donidalorsen) launch in HAE
Financial guidance raise and revenue outlook
Revenue
$246.09M
▲ 87% YoY Diluted EPS
$-0.56
Gross margin
98.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Ionis Pharmaceuticals Inc (IONS) Q4 2025 Earnings Call Transcript
Confident tone
Olezarsen in severe hypertriglyceridemia
DAWNZERA launch in HAE
TRYNGOLZA launch and FCS franchise
Revenue
$203.33M
▼ 10.3% YoY Diluted EPS
$-1.41
Gross margin
96.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-29
Ionis Pharmaceuticals Inc (IONS) Q3 2025 Earnings Call Transcript
Confident tone
Tringolza launch (FCS)
Olezarsen (olazarsen/olisarcin) in SHTG
Donzara / HAE launch
Revenue
$156.72M
▲ 17.1% YoY Diluted EPS
$-0.80
Gross margin
98.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Ionis Pharmaceuticals Inc (IONS) Q2 2025 Earnings Call Transcript
Confident tone
Donidalorsen approval and HAE launch preparation
CORE1/CORE2 acute pancreatitis readout risk
Olezarsen severe hypertriglyceridemia opportunity
Revenue
$452.05M
▲ 100.7% YoY Diluted EPS
$0.70
Gross margin
99.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-30
Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Transcript
Confident tone
TRYNGOLZA (olezarsen/FCS) launch
donidalorsen / hereditary angioedema (HAE)
Raised 2025 financial guidance
Revenue
$131.61M
▲ 10.1% YoY Diluted EPS
$-0.93
Gross margin
98.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-19
Ionis Pharmaceuticals Inc (IONS) Q4 2024 Earnings Call Transcript
Confident tone
Tringolza independent launch in FCS
Pipeline of independent launches
Olezarsen SHTG opportunity
Revenue
$226.58M
▼ 30.2% YoY Diluted EPS
$-0.66
Gross margin
98.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Transcript
Confident tone
Olezarsen launch and FCS approval
ION582 / Angelman syndrome program
Donidalorsen for HAE
Revenue
$133.81M
▼ 7.2% YoY Diluted EPS
$-0.95
Gross margin
99.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Ionis Pharmaceuticals Inc (IONS) Q2 2024 Earnings Call Transcript
Confident tone
WAINUA launch and global expansion
Olezarsen for FCS and sHTG
QALSODY availability and ALS
Revenue
$225.25M
▲ 19.6% YoY Diluted EPS
$-0.45
Gross margin
98.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Ionis Pharmaceuticals Inc (IONS) Q1 2024 Earnings Call Transcript
Confident tone
Olezarsen for FCS and SHTG
Donidalorsen for HAE
ION224 / DGAT2 for MASH and partnering
Revenue
$119.50M
▼ 8.4% YoY Diluted EPS
$-0.98
Gross margin
98.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-21
Ionis Pharmaceuticals Inc (IONS) Q4 2023 Earnings Call Transcript
Confident tone
WAINUA launch and ATTR franchise
Donidalorsen for HAE
Olezarsen for FCS
Revenue
$324.50M
▲ 113.6% YoY Diluted EPS
$-0.06
Gross margin
99.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Ionis Pharmaceuticals Inc (IONS) Q3 2023 Earnings Call Transcript
Revenue
$144.21M
▼ 9.7% YoY Diluted EPS
$-1.03
Gross margin
98.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Ionis Pharmaceuticals Inc (IONS) Q2 2023 Earnings Call Transcript
Revenue
$188.41M
▲ 40.8% YoY Diluted EPS
$-0.60
Gross margin
98.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Ionis Pharmaceuticals Inc (IONS) Q1 2023 Earnings Call Transcript
Revenue
$130.52M
▼ 8% YoY Diluted EPS
$-0.87
Gross margin
99.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
Ionis Pharmaceuticals Inc (IONS) Q4 2022 Earnings Call Transcript
Revenue
$151.89M
▼ 65.5% YoY Diluted EPS
$-0.37
▼ 126.2% YoY Gross margin
97.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Ionis Pharmaceuticals Inc (IONS) Q3 2022 Earnings Call Transcript
Revenue
$159.77M
▲ 20% YoY Diluted EPS
$-0.33
Gross margin
99.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Ionis Pharmaceuticals Inc (IONS) Q2 2022 Earnings Call Transcript
Revenue
$133.79M
▲ 6.4% YoY Diluted EPS
$-0.74
Gross margin
96.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Ionis Pharmaceuticals Inc (IONS) Q1 2022 Earnings Call Transcript
Revenue
$141.92M
▲ 27.2% YoY Diluted EPS
$-0.46
Gross margin
97.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Ionis Pharmaceuticals Inc (IONS) Q4 2021 Earnings Call Transcript
Revenue
$440.01M
▲ 51.6% YoY Diluted EPS
$1.41
Gross margin
99.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Ionis Pharmaceuticals Inc (IONS) Q3 2021 Earnings Call Transcript
Revenue
$133.09M
▼ 16.9% YoY Diluted EPS
$-0.58
Gross margin
97.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Ionis Pharmaceuticals Inc (IONS) Q2 2021 Earnings Call Transcript
Revenue
$125.75M
▼ 13.6% YoY Diluted EPS
$-0.57
Gross margin
97.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Ionis Pharmaceuticals Inc (IONS) Q1 2021 Earnings Call Transcript
Revenue
$111.61M
▼ 16.3% YoY Diluted EPS
$-0.64
Gross margin
97.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
Ionis Pharmaceuticals Inc (IONS) Q4 2020 Earnings Call Transcript
Revenue
$290.28M
▼ 41.2% YoY Diluted EPS
$-2.54
▼ 298.4% YoY Gross margin
98.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Ionis Pharmaceuticals Inc (IONS) Q3 2020 Earnings Call Transcript
Revenue
$160.08M
▼ 4.7% YoY Diluted EPS
$-0.18
▼ 200% YoY Gross margin
98.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Ionis Pharmaceuticals Inc (IONS) Q2 2020 Earnings Call Transcript
Revenue
$145.54M
▼ 11.2% YoY Diluted EPS
$-0.18
Gross margin
97.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Ionis Pharmaceuticals Inc (IONS) Q1 2020 Earnings Call Transcript
Revenue
$133.37M
▼ 55.1% YoY Diluted EPS
$-0.28
▼ 145.2% YoY Gross margin
98.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-26
Ionis Pharmaceuticals Inc (IONS) Q4 2019 Earnings Call
Revenue
$493.68M
▲ 157% YoY Diluted EPS
$1.28
▼ 42.1% YoY Gross margin
99.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–33 of 33 webcasts
Key facts
CIK
874015
CUSIP
462222100
13F (30d)
363 filings
328 filers
Visit website
Investor relations